These results demonstrate that macrophage CREBZF is required for the beneficial effects of bromocriptine mesylate on the attenuation of ATM activation, insulin resistance, and type 2 diabetes in mice, and CREBZF may serve as a therapeutic target to relieve a ATM proinflammatory activation in insulin resistance. This evidence concerns the gene CREBZF and type 2 diabetes mellitus.